Aroa Biosurgery Ltd (AU:ARX) has released an update.
Aroa Biosurgery Ltd, a soft tissue regeneration company, reported strong Q1 FY25 financial results with cash receipts of NZ$17.8 million, despite a planned net cash outflow from operations of NZ$3.6 million, attributed to post-financial year payments and clinical trial expenses. The company maintains its FY25 revenue and EBITDA profit guidance of NZ$80-87 million and NZ$2-6 million, respectively, and expects to become operating cash flow positive in the second half of FY25. Additionally, Aroa Biosurgery saw significant commercial progress with a 11% growth in active accounts in the US and robust ex-US sales, including new regulatory approvals and distributor appointments in various countries.
For further insights into AU:ARX stock, check out TipRanks’ Stock Analysis page.
